Table 4.
T1 Groups | T2 Groups | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
FSC vs. Average |
FSC vs. MS | Average vs. MS |
A vs. EFAS | A vs. SFPS | SFPS vs. PFAS |
EFAS vs. MS | PFAS vs. MS | SFPS vs. MS | PFAS vs. A | |
Sociodemographic | ||||||||||
Age | --- | 0.95 (0.90, 1.00) |
0.94 (0.90, 0.98) |
--- | --- | --- | --- | --- | --- | --- |
Married vs. not married | 0.33 (0.13, 0.80) |
--- | --- | 4.55 (1.13, 18.35) |
6.24 (1.36, 28.66) |
--- | --- | --- | --- | --- |
Medical | ||||||||||
Stage at dx: II (vs. III) | --- | --- | 2.92 (1.13, 7.58) |
--- | --- | --- | --- | --- | --- | --- |
Surgical intervenion | ||||||||||
Lumpect vs. “Other” | --- | --- | 3.24 (1.01, 10.42) |
--- | --- | --- | --- | --- | --- | --- |
Mastect vs. “Other” | --- | --- | 3.43 (1.07, 11.01) |
--- | --- | --- | --- | --- | --- | --- |
BMI | --- | --- | --- | --- | --- | 1.17 (1.02, 1.33) |
--- | --- | --- | --- |
Current medications | ||||||||||
Analgesics | --- | 4.22 (1.26, 14.16) |
--- | --- | --- | --- | --- | --- | --- | --- |
Antidep | --- | --- | --- | --- | --- | --- | 4.38 (1.19, 16.13) |
--- | --- | --- |
Minor tranq | --- | --- | --- | 0.17 (0.04, 0.68) |
--- | --- | 8.95 (2.38, 33.62) |
--- | --- | --- |
Comorbidities | ||||||||||
Asthma | --- | 6.14 (1.14, 33.07) |
--- | --- | --- | --- | 18.91 (1.92, 185.95) |
11.14 (1.08, 115.54) |
19.50 (1.80, 211.21) |
|
Arthritis | --- | --- | --- | --- | --- | --- | --- | 3.58 (1.00, 12.81) |
--- | 5.09 (1.08, 24.02) |
“Other” disease | --- | 4.90 (1.15, 20.96) |
--- | --- | 0.09 (0.01, 0.98) |
--- | --- | --- | --- | 12.50 (1.32, 118.48) |
Note. Only pairwise comparisons that were statistically significantly different are presented in this table (all ps ≤ .05). FSC = Fatigued with sleep complaints; MS – Minimal symptoms; SFPS = Severely fatigued with poor sleep; EFAS = Emotionally fatigued with average sleep; PFAS = Physically fatigued with average sleep; A = Average; Lumpect = Lumpectomy; Mastect = Mastectomy; Antidep = Antidepressants; Minor tranq = minor tranquilizers. For surgical intervention “other’ indicates double mastectomy or neoadjuvant chemotherapy. For comorbidities “other’ indicates any disease not specifically queried.